DALLAS, June 17, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring biopharmaceutical stock Allos Therapeutics Inc. (Nasdaq:ALTH). The report includes the most ...
Allos Therapeutics, Inc. (ALTH) will visit the NASDAQ MarketSite in New York City's Times Square. In honor of the occasion and in honor of patients with blood cancers and their families, Dr. Charles ...
Allos Therapeutics (ALTH) is small-cap cancer biotech which filed a NDA on 3/25/09 for pralatrexate (PDX) in the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). ALTH ...
WESTMINSTER, Colo., Sep 25, 2009 (BUSINESS WIRE) -- Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that last night the U.S. Food and Drug Administration (FDA) granted accelerated approval for ...
Allos Therapeutics (Nasdaq:ALTH) is trading at unusually high volume Wednesday with 8.2 million shares changing hands. It is currently at 6.4 times its average daily volume and trading down 5 cents ...
Spectrum Pharmaceuticals (SPPI) and Allos Therapeutics (ALTH) announced that Spectrum has provided an additional extension of the offer period in connection with its tender offer to purchase all of ...
Reports 27 percent sequential increase in FOLOTYN(R) fourth quarter demand sales over third quarter 2010 WESTMINSTER, Colo., Jan 11, 2011 (BUSINESS WIRE) -- Allos Therapeutics, Inc. (NASDAQ: ALTH) ...
WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq: ALTH) announced today that the Agreement and Plan of Merger and Reorganization ("the Merger Agreement") entered into by and among ...
Allos Therapeutics, Inc.’s third quarter loss narrowed, beating estimates. Allos Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs ...
Henderson-based Spectrum Pharmaceuticals Inc. said Thursday it would acquire Allos Therapeutics Inc. in a deal valued as much as $206 million. Terms of the acquisition call for Spectrum to pay $1.82 a ...
We have recently downgraded Allos Therapeutics Inc. ( ALTH) to Neutral from Outperform with a target price of $1.50. The failure of Allos' deal with AMAG Pharma ( AMAG) in October 2011 has reverted ...
WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ:ALTH) today announced the Company will hold a webcast conference call on Wednesday, September 2, 2009 to discuss the outcome of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results